By Kamal Choudhury (Reuters) -Vaccine maker Novavax's shares plunged nearly 20% at market close on Thursday, after Health and ...

Novavax Inc. shares plunged as much as 26% after US Health and Human Services Secretary Robert F. Kennedy Jr. raised doubts ...

The US Food and Drug Administration has delayed granting full approval of Novavax’s Covid-19 vaccine despite it being on ...

Concern is growing among public health experts that anti-vaccine sentiments within federal and state governments may derail ...

Novavax (NASDAQ: NASDAQ:NVAX) stock plummeted 24% after comments from Health and Human Services Secretary Robert F. Kennedy Jr. suggested a shift in government priorities away from the company’s ...

Amid a period of great upheaval at the agency, the FDA has missed its deadline to decide on approval for Novavax’s COVID-19 ...

Novavax started the week hoping the FDA would issue a full approval of its Covid vaccine. But the decision never came.

The FDA was supposed to make a final decision about approval of Novavax's COVID-19 vaccine this week, but that deadline has ...

Shuren, who retired from his spot leading the FDA’s Center for Devices and Radiological Health (CDRH) in 2024, said last week ...

The FDA was scheduled to release its decision on Novavax’s updated, protein-based COVID-19 vaccine on April 1, but the agency ...

The agency is sitting on a decision to grant full approval for Novavax’s shot, days after top vaccine regulator pushed out.